First Solar, Inc. earnings call
CURE launch complete; rollout through 2028 could add $0.6B revenue.
First Solar reported a record Q1 with strong margins and EBITDA, but the key signals were about the policy-dependent future of its US and international capacity. Management reiterated its selective booking strategy, waiting on the Section 232 decision to unlock demand and potentially re-engage its Southeast Asian capacity. The competitive landscape is being shaped by IP enforcement against TopCon and the ramp of its new CURE technology. Record Q1 revenue of $1B and adjusted EBITDA of $520M, exceeding guidance.
Buzzberg read CURE launch complete; rollout through 2028 could add $0.6B revenue. First Solar reported a record Q1 with strong margins and EBITDA, but the key signals were about the policy-dependent future of its US and international capacity. Management reiterated its selective booking strategy, waiting on the Section 232 decision to unlock demand and potentially re-engage its Southeast Asian capacity. The competitive landscape is being shaped by IP enforcement against TopCon and the ramp of its new CURE technology. Record Q1 revenue of $1B and adjusted EBITDA of $520M, exceeding guidance. Read full analysisCollapse analysis
First Solar reported a record Q1 with strong margins and EBITDA, but the key signals were about the policy-dependent future of its US and international capacity. Management reiterated its selective booking strategy, waiting on the Section 232 decision to unlock demand and potentially re-engage its Southeast Asian capacity. The competitive landscape is being shaped by IP enforcement against TopCon and the ramp of its new CURE technology. Record Q1 revenue of $1B and adjusted EBITDA of $520M, exceeding guidance.
- Gross bookings of 1.7GW, with US bookings at ~$0.34/W ASP, maintaining discipline.
- Management reaffirmed FY2026 guidance, expecting stronger H2 margins.
- CURE technology launch complete, aiming for 8% energy yield advantage; pricing shifts to base ASPs, reducing adders.
What matters now
The highest-signal changes from the call.
Strong U.S. bookings at 35 cents per watt.
North American production largely committed through 2028.
Show 3 more callouts
Trade IP investigation set to proceed with initial determination within 11 months.
Perovskite pilot line planned for 2027.
Tariff assumptions may change if 232 decision alters policy.
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $1.0442B | -38% QoQ |
| EPS | $3.22 | -33% QoQ |
| Gross margin | 46.55% | Reported |
| Operating margin | 33.07% | Reported |
| Free cash flow | $-0.3334B | Reported |
| Capex | $0.1185B | Reported |
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Free cash flow | FY2026 Q2 | $400–$500 | $450 | Maintained |
| Units | FY2026 Q2 | 3.4–4 | 3.7 | Maintained |
Management read
Measured
Management expressed confidence in strategic positioning and technology advantages, but remained cautious regarding pending policy and tariff decisions, emphasizing selective booking and disciplined approach.
Investment and capacity
Management outlined capacity investments including the South Carolina finishing facility and a perovskite pilot line, with capital expenditures of $119 million in Q1, primarily for the South Carolina facility. They expect the South Carolina facility to start production in the second half of 2026.
Companiesreturns since call
Competitors
If Tesla adopts TopCon for its US manufacturing, it may infringe on First Solar's IP, potentially leading to licensing negotiations or legal action.
Evidence
“I do think it's one of the challenges that you know, tesla's going to have to figure out what what technology they go with and how do they get freedom to operate”
Supply-chain alpha · 3returns since call
First Solar holds ~1.8-2GW of fully-finished module capacity in Malaysia/Vietnam that is tethered to the 232 tariff decision.
Evidence
“There's only about, call it 1.8 gigawatts, maybe closer to two of real capacity. So what we're talking about is from a full-size finishing module capacity perspective.”
First Solar is pricing its new CURE technology into base ASPs, reducing the prevalence of technology adjusters in new contracts.
Evidence
“For the windows of which we for sure are going to be delivering the cure product, we'll just price it as the contract. And you won't necessarily continue to see the adders.”
India module demand is strong, with ASPs at ~$0.20/watt, but Q3 demand softens.
Evidence
“Q3, we see a little bit of softness generally in India, and then you'll see a stronger Q4.”
Methodology & coverage
Management-only analysis. All 1 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.